180 related articles for article (PubMed ID: 15917157)
41. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
42. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
43. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
[TBL] [Abstract][Full Text] [Related]
44. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women.
Joffe H; Hall JE; Gruber S; Sarmiento IA; Cohen LS; Yurgelun-Todd D; Martin KA
Menopause; 2006; 13(3):411-22. PubMed ID: 16735938
[TBL] [Abstract][Full Text] [Related]
45. Comparison of a transdermal continuous combined and an interrupted progestogen HRT.
Cameron ST; Glasier AF; Gebbie A; Dewart H; Baird DT
Maturitas; 2006 Jan; 53(1):19-26. PubMed ID: 16325020
[TBL] [Abstract][Full Text] [Related]
46. [Comparative study of the acceptability of a new estradiol Tx 11323 (A) gel and a transdermal matrix system].
Gelas B; Thébault J; Roux I; Herbrecht F; Zartarian M
Contracept Fertil Sex; 1997 Jun; 25(6):470-4. PubMed ID: 9280552
[TBL] [Abstract][Full Text] [Related]
47. Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study.
Fait T; Vrablik M; Cibula D; Masata J; Hill M; Trnkova B
Neuro Endocrinol Lett; 2006 Oct; 27(5):665-8. PubMed ID: 17159824
[TBL] [Abstract][Full Text] [Related]
48. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life.
Yaffe K; Vittinghoff E; Ensrud KE; Johnson KC; Diem S; Hanes V; Grady D
Arch Neurol; 2006 Jul; 63(7):945-50. PubMed ID: 16831962
[TBL] [Abstract][Full Text] [Related]
49. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
[TBL] [Abstract][Full Text] [Related]
50. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms.
Van Leusden HA; Albertyn G; Verlaine C; Van Ruymbeke J
Int J Fertil Menopausal Stud; 1993; 38(4):210-8. PubMed ID: 8401679
[TBL] [Abstract][Full Text] [Related]
51. A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology.
Odabaşi AR; Yüksel H; Demircan SS; Kaçar DF; Culhaci N; Ozkara EE
J Postgrad Med; 2007; 53(4):221-7. PubMed ID: 18097108
[TBL] [Abstract][Full Text] [Related]
52. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet.
Weisberg E; Ayton R; Darling G; Farrell E; Murkies A; O'Neill S; Kirkegard Y; Fraser IS
Climacteric; 2005 Mar; 8(1):83-92. PubMed ID: 15804736
[TBL] [Abstract][Full Text] [Related]
53. The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women.
Castelo-Branco C; Coloma JL
Gynecol Endocrinol; 2010 Jan; 26(1):23-9. PubMed ID: 19639494
[TBL] [Abstract][Full Text] [Related]
54. Intranasal estradiol: new formulation. Intranasal oestrogen delivery system: just a gimmick.
Prescrire Int; 2002 Dec; 11(62):163-5. PubMed ID: 12469692
[TBL] [Abstract][Full Text] [Related]
55. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
Utian WH; Speroff L; Ellman H; Dart C
Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
[TBL] [Abstract][Full Text] [Related]
56. Clinical experience with Systen, a new transdermal form of hormone replacement therapy.
Corson SL
Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():36-44. PubMed ID: 8499958
[TBL] [Abstract][Full Text] [Related]
57. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
[TBL] [Abstract][Full Text] [Related]
58. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
[TBL] [Abstract][Full Text] [Related]
59. Two routes of hormonal replacement therapy in symptomatic menopausal women after kidney transplantation.
Pietrzak B; Wielgos M; Kaminski P; Bobrowska K
Neuro Endocrinol Lett; 2006 Jun; 27(3):387-91. PubMed ID: 16816826
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group.
Studd J; Pornel B; Marton I; Bringer J; Varin C; Tsouderos Y; Christiansen C
Lancet; 1999 May; 353(9164):1574-8. PubMed ID: 10334256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
